[Phase II study of 4'-O-tetrahydropyranyl-adriamycin (THP-ADM) in patients with gynecological cancer].

Abstract

We conducted a joint phase II study in 76 patients with gynecological cancer (42 patients with ovarian cancer, 22 patients with cervical cancer, 10 patients with endometrial cancer and 2 patients with vaginal cancer). The response rate was 25.0% in the patients with ovarian cancer, 13.3% in those with cervical cancer, and 28.6% in those with endometrial cancer. The overall response rate was 23.1%. When the patients were classified according to dose schedules, the highest response rate was obtained in the group administered THP-ADM at a dose of 60 mg per body by single i.v. injection at 3-week intervals. Such side effects as myelosuppression and gastrointestinal disturbances were observed, but alopecia, a marked side-effect of ADM administration, was mild, and no cardiac toxicity was seen in any of the patients.

• Authors: T Kato, H Nishimura, J Umezu, S Takeuchi, K Kanazawa, H Inoue, M Suzuki, M Hirono, T Suzuki, H Okajima
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 12 Issue 10 Pg. 1962-7 (Oct 1985) ISSN: 0385-0684 [Print] Japan
• PMID: 4051511 (Publication Type: English Abstract, Journal Article)

Chemical References

• Doxorubicin
• pirarubicin

Topics

• Adult
• Aged
• Doxorubicin (administration & dosage, analogs & derivatives, therapeutic use)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Genital Neoplasms, Female (drug therapy)
• Humans
• Middle Aged
• Ovarian Neoplasms (drug therapy)
• Uterine Cervical Neoplasms (drug therapy)
• Uterine Neoplasms (drug therapy)
• Vaginal Neoplasms (drug therapy)